A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors

Trial Profile

A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs MM-151 (Primary) ; Irinotecan
  • Indications Breast cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2016 Final results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2016 Results published in a Merrimack Pharmaceuticals media release.
    • 18 May 2016 Results will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Merrimack Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top